Logo image of GRAL

GRAIL INC (GRAL) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:GRAL - US3847471014 - Common Stock

116.06 USD
+14.99 (+14.83%)
Last: 1/22/2026, 5:47:50 PM
116 USD
-0.06 (-0.05%)
After Hours: 1/22/2026, 5:47:50 PM

GRAL Key Statistics, Chart & Performance

Key Statistics
Market Cap4.52B
Revenue(TTM)141.83M
Net Income(TTM)-406.24M
Shares38.98M
Float35.01M
52 Week High118.84
52 Week Low20.44
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-11.64
PEN/A
Fwd PEN/A
Earnings (Next)02-19
IPO2024-06-12
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
GRAL short term performance overview.The bars show the price performance of GRAL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 50 100 150

GRAL long term performance overview.The bars show the price performance of GRAL in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of GRAL is 116.06 USD. In the past month the price increased by 23.01%. In the past year, price increased by 305.66%.

GRAIL INC / GRAL Daily stock chart

GRAL Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to GRAL. When comparing the yearly performance of all stocks, GRAL is one of the better performing stocks in the market, outperforming 98.61% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

GRAL Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to GRAL. No worries on liquidiy or solvency for GRAL as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GRAL Financial Highlights

Over the last trailing twelve months GRAL reported a non-GAAP Earnings per Share(EPS) of -11.64. The EPS increased by 90.18% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -15.62%
ROE -18.14%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%37.56%
Sales Q2Q%26.33%
EPS 1Y (TTM)90.18%
Revenue 1Y (TTM)-21.4%

GRAL Forecast & Estimates

10 analysts have analysed GRAL and the average price target is 107.1 USD. This implies a price decrease of -7.72% is expected in the next year compared to the current price of 116.06.

For the next year, analysts expect an EPS growth of 82.14% and a revenue growth 18.12% for GRAL


Analysts
Analysts80
Price Target107.1 (-7.72%)
EPS Next Y82.14%
Revenue Next Year18.12%

GRAL Ownership

Ownership
Inst Owners66.06%
Ins Owners1.06%
Short Float %14.86%
Short Ratio5.53

About GRAL

Company Profile

GRAL logo image GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 1,000 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

Company Info

GRAIL INC

1525 O'brien Drive

Menlo Park CALIFORNIA US

Employees: 1000

GRAL Company Website

Phone: 18336942553

GRAIL INC / GRAL FAQ

Can you describe the business of GRAIL INC?

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 1,000 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.


Can you provide the latest stock price for GRAIL INC?

The current stock price of GRAL is 116.06 USD. The price increased by 14.83% in the last trading session.


Does GRAIL INC pay dividends?

GRAL does not pay a dividend.


What is the ChartMill technical and fundamental rating of GRAL stock?

GRAL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


On which exchange is GRAL stock listed?

GRAL stock is listed on the Nasdaq exchange.


What is GRAIL INC worth?

GRAIL INC (GRAL) has a market capitalization of 4.52B USD. This makes GRAL a Mid Cap stock.


Can you provide the ownership details for GRAL stock?

You can find the ownership structure of GRAIL INC (GRAL) on the Ownership tab.